(ANGO) AngioDynamics - NASDAQ
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 499m USD | Total Return: 11.9% in 12m
Avg Turnover: 3.38M
Qual. Beats: 1
Rev. Trend: -61.6%
Qual. Beats: 0
Warnings
High Debt/EBITDA (6.2) with thin interest coverage (-10.7)
Interest Coverage Ratio -10.7 is critical
Altman Z'' -2.05 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
AngioDynamics Inc. (NASDAQ: ANGO) is a medical technology firm specializing in the design and manufacture of devices for peripheral vascular disease, oncology, and surgical applications. Its primary product lines include the Auryon Atherectomy system for lesion removal and the AlphaVac mechanical thrombectomy system for blood clot aspiration. The company also provides soft tissue ablation technologies, such as the NanoKnife IRE and Solero Microwave systems, alongside a range of diagnostic and interventional catheters.
The company operates within the medical device sector, a capital-intensive industry characterized by rigorous FDA regulatory cycles and high research and development requirements. AngioDynamics utilizes a direct sales force and international distributors to target hospitals and outpatient clinics, focusing on minimally invasive alternatives to traditional surgical procedures. Investors may find additional context on these market dynamics by reviewing the data available on ValueRay.
- Auryon atherectomy and AlphaVac adoption drives high-margin Med Tech segment revenue growth
- FDA regulatory clearance timeline for NanoKnife IRE system impacts oncology market valuation
- Divestiture of legacy businesses streamlines operations toward higher-growth vascular and oncology portfolios
- Supply chain stabilization and manufacturing efficiencies determine gross margin expansion targets
| Net Income: -31.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 10.45 > 1.0 |
| NWC/Revenue: 28.52% < 20% (prev 33.28%; Δ -4.76% < -1%) |
| CFO/TA 0.02 > 3% & CFO 4.45m > Net Income -31.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.6m) vs 12m ago 1.82% < -2% |
| Gross Margin: 53.45% > 18% (prev 54.36%; Δ -0.90% > 0.5%) |
| Asset Turnover: 114.9% > 50% (prev 99.27%; Δ 15.63% > 0%) |
| Interest Coverage Ratio: -10.75 > 6 (EBIT TTM -28.7m / Interest Expense TTM 2.67m) |
| A: 0.34 (Total Current Assets 155.6m - Total Current Liabilities 66.1m) / Total Assets 260.7m |
| B: -1.74 (Retained Earnings -454.5m / Total Assets 260.7m) |
| C: -0.11 (EBIT TTM -28.7m / Avg Total Assets 273.0m) |
| D: 1.99 (Book Value of Equity 173.4m / Total Liabilities 87.3m) |
| Altman-Z'' = -2.05 = D |
| DSRI: 0.84 (Receivables 45.6m/49.0m, Revenue 313.7m/283.3m) |
| GMI: 1.02 (GM 54.36% / 53.45%) |
| AQI: 1.03 (AQ_t 0.29 / AQ_t-1 0.28) |
| SGI: 1.11 (Revenue 313.7m / 283.3m) |
| TATA: -0.14 (NI -31.4m - CFO 4.45m) / TA 260.7m) |
| Beneish M = -3.06 (Cap -4..+1) = AA |
As of June 15, 2026, the stock is trading at USD 12.10 with a total of 227,274 shares traded.
Over the past week, the price has changed by +1.34%,
over one month by +9.70%,
over three months by +13.40% and
over the past year by +11.93%.
AngioDynamics has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ANGO.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 18 | 48.8% |
P/E Forward = 96.1538
P/S = 1.591
P/B = 2.9269
P/EG = 1.4079
Revenue TTM = 313.7m USD
EBIT TTM = -28.7m USD
EBITDA TTM = -5.44m USD
Long Term Debt = unknown (none)
Short Term Debt = 1.84m USD (from shortTermDebt, last fiscal year)
Debt = 3.95m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -33.9m USD (calculated: Debt 3.95m - CCE 37.8m)
Enterprise Value = 465.3m USD (499.1m + Debt 3.95m - CCE 37.8m)
Interest Coverage Ratio = -10.75 (Ebit TTM -28.7m / Interest Expense TTM 2.67m)
EV/FCF = 309.6x (Enterprise Value 465.3m / FCF TTM 1.50m)
FCF Yield = 0.32% (FCF TTM 1.50m / Enterprise Value 465.3m)
FCF Margin = 0.48% (FCF TTM 1.50m / Revenue TTM 313.7m)
Net Margin = -10.00% (Net Income TTM -31.4m / Revenue TTM 313.7m)
Gross Margin = 53.45% ((Revenue TTM 313.7m - Cost of Revenue TTM 146.0m) / Revenue TTM)
Gross Margin QoQ = 52.89% (prev 53.05%)
Tobins Q-Ratio = 1.78 (Enterprise Value 465.3m / Total Assets 260.7m)
Interest Expense / Debt = 67.69% (Interest Expense 2.67m / Debt 3.95m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -22.7m (EBIT -28.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.35 (Total Current Assets 155.6m / Total Current Liabilities 66.1m)
Debt / Equity = 0.02 (Debt 3.95m / totalStockholderEquity, last quarter 173.4m)
Debt / EBITDA = 6.22 (negative EBITDA) (Net Debt -33.9m / EBITDA -5.44m)
Debt / FCF = -22.53 (Net Debt -33.9m / FCF TTM 1.50m)
Total Stockholder Equity = 177.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.50% (Net Income -31.4m / Total Assets 260.7m)
RoE = -17.65% (Net Income TTM -31.4m / Total Stockholder Equity 177.9m)
RoCE = -14.75% (EBIT -28.7m / Capital Employed (Total Assets 260.7m - Current Liab 66.1m))
RoIC = -12.54% (negative operating profit) (NOPAT -22.7m / Invested Capital 180.8m)
WACC = 6.80% (E(499.1m)/V(503.1m) * Re(6.85%) + (debt cost/tax rate unavailable))
Discount Rate = 6.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 1.51%
[DCF] Terminal Value 75.44% ; FCFF base≈1.50m ; Y1≈1.51m ; Y5≈1.60m
[DCF] Fair Price = 1.42 (EV 24.9m - Net Debt -33.9m = Equity 58.7m / Shares 41.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.90 | # QB: 1
Revenue Correlation: -61.63 | Revenue CAGR: -4.15% | SUE: 0.43 | # QB: 0
EPS current Quarter (2026-08-31): EPS=-0.10 | Chg30d=-75.82% | Revisions=+0% | Analysts=3
[Analyst] Revisions Ratio: +0%